Human Milk Oligosaccharides (HMO) Market Size, Share, Growth, and Industry Analysis, By Type (2'-FL & 3-FL, Sialyllactose, LNT & LNnT), By Application (Infant Formula, Functional Food & Beverages, Food/Medical Supplements, Others), and Regional Forecast to 2033

HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET OVERVIEW

Human Milk Oligosaccharides (HMO) Market Size was estimated at USD 443.02 million in 2024 and it is expected to grow from USD 509.92 million in 2025 to USD 675.54 million by 2033. The Market CAGR (growth rate) is expected to be around 15.1% during the forecast period (2025 - 2033).

The Human Drain Oligosaccharides (HMO) market report gives a comprehensive examination of current designs, growth drivers, and challenges inside the HMO industry. HMOs are specialized glycans special to human breast drain, esteemed for their benefits in infant intestine health and immunity. Their applications are expanding past newborn child equation, coming to into useful foods and supplements, driven by rising awareness of their health benefits. The report digs into the sorts of HMOs, counting 2'-FL, 3-FL, and Sialyllactose, among others, offering experiences on how each section is advancing inside the market.

This report could be a profitable asset for partners, speculators, and researchers pointing to get it the HMO market landscape. It incorporates market division by sort and application and offers insights into the generation complexities and high costs related with HMO synthesis, which as of now limit large-scale production. Also, regional analysis highlights the changing levels of demand over North America, Europe, and Asia-Pacific, identifying key players and rising trends that are forming market growth.

• • 

    Request a Free sample to learn more about this report.

KEY FINDINGS

• Market Size and Growth: The Human Milk Oligosaccharides (HMO) Market size was USD 443.02 Million in 2024, is projected to grow to USD 509.92 Million by 2025 and exceed USD 675.54 Million by 2033, with a CAGR of 15.1%.

• Key Market Driver: Growing demand for infant formulas enriched with HMOs has skyrocketed—over 65% of newly launched formula products in 2023 featured one or more HMOs.

• Major Market Restraint: High production costs remain a concern; the fermentation process for synthesizing HMOs can require up to 45 hours of controlled bioreactor time per batch.

• Emerging Trends: Adult health and gut microbiome applications are gaining traction—clinical trials around 2’-FL and LNnT in adult probiotics rose by 22% in 2023.

• Regional Leadership: Europe held a dominant share in 2024, accounting for nearly 38% of global HMO usage, driven by regulatory approvals and infant nutrition innovation hubs in Germany and the Netherlands.

• Competitive Landscape: About 8 major players control the majority of the global output, with DSM, BASF, and Glycom among the top suppliers investing in new strains and synthesis pathways.

• Market Segmentation: 2’-Fucosyllactose (2’-FL) remains the most widely used type, comprising roughly 55% of HMO ingredients in infant formula by volume in 2024.

• Recent Development: In late 2023, DSM-Firmenich announced the expansion of its HMOs portfolio with a new facility in Switzerland aiming to increase 2’-FL production capacity by 35%.

COVID-19: IMPACT

"Rising Domestic Amusement Request Flashes Chip Advancement in the midst of Supply Chain Disturbances"

Rising Wellbeing Mindfulness Drives Demand for HMOs despite Production Disruptions : The Global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to the market’s growth and demand returning to pre-pandemic levels.

The COVID-19 widespread disturbed the HMO market, influencing generation and supply chains worldwide. Restrictions on fabricating and logistics driven to temporary shortages, while expanding wellbeing awareness impelled request for HMOs, particularly in infant nutrition. As consumers centered on resistance and in general health, intrigued in HMO applications past infant formula grew. This move has encouraged companies to prioritize R&D for cost-effective production techniques to meet the rising request over various locales.

LATEST TREND

"Innovative Generation Strategies Drive HMO Market Growth and Accessibility"

A significant trend driving market growth within the HMO industry is the advancement of progressed, cost-effective generation techniques. Companies are increasingly investing in synthetic science and aging forms to diminish the high manufacturing costs traditionally related with HMOs. These methods not as it were streamline generation but also extend the potential applications of HMOs in grown-up health supplements and useful foods. As more proficient innovations rise, they are enabling more extensive market accessibility and bolstering request, positioning HMOs as essential components in different health-oriented items.

• • 

    Request a Free sample to learn more about this report.

HUMAN MILK OLIGOSACCHARIDES (HMO) MARKET SEGMENTATION

By Type

Based on Type, the global market can be categorized into 2'-FL & 3-FL, Sialyllactose, LNT & LNnT

• 2'-FL & 3-FL: These are the most prevalent human milk oligosaccharides found in breast milk, serving as prebiotics that advance the growth of beneficial gut bacteria. Their predominant part in infant equation enhances immune protection and digestive health in infants.

• Sialyllactose: Sialyllactose is known for its ability to back brain development and cognitive work in infants. It too plays a critical part in immune response, giving extra assurance against infections by inhibiting pathogen official.

• LNT & LNnT: LNT and LNnT contribute to intestine wellbeing by acting as prebiotics, fostering the growth of useful microbiota. Their structural diversity permits them to serve various functions, including pathogen resistance and tweak of immune responses.

By Application

Based on application, the global market can be categorized into Infant Formula, Functional Food & Beverages, Food/Medical Supplements, Others

• Infant Formula: Usually the largest application segment, as HMOs are incorporated into infant formulas to mimic the benefits of breast drain, giving essential prebiotic bolster for creating infants. The presence of HMOs in formula helps in digestion, gut wellbeing, and immune system development.

• Functional Food & Beverages: In this application, HMOs are utilized to enhance the wellbeing benefits of different nourishment things and refreshments, focusing on health-conscious clients. They offer prebiotic properties that support intestine wellbeing and overall well-being, engaging to a broader audience past newborn children.

• Food/Medical Supplements: HMOs are increasingly utilized in dietary supplements pointed at improving gut health and boosting immunity. These items are marketed for both infants and adults, capitalizing on the growing drift of preventative healthcare through nutrition.

By Others

• Others: This category includes various niche applications such as animal nourish and specialty items designed for specific health conditions. HMOs can enhance the nutritional profile and health benefits of these items, catering to rising markets and specialized dietary needs

MARKET DYNAMICS

Market dynamics include driving and restraining factors, opportunities and challenges stating the market conditions.

Driving Factors

"Rising Customer Request for Smart Highlights Drives Market Development"

The consumer preference for Human Milk Oligosaccharides (HMO) Market growth. That equipped with advanced features is a significant driving force behind market expansion. As family units look for improved entertainment options, the request for high-quality video streaming, gaming capabilities, and interactive functionalities rises. This trend encourages producers to invest in developing modern Smart TV Chips that can support these highlights, eventually driving to increased deals and a more competitive market scene.

"Extending of HMOs Driving Applications"

The flexibility of HMOs is driving their selection over different sectors past infant nutrition. As research reveals the potential wellbeing benefits of HMOs for grown-ups, counting improved gut microbiota and resistant reactions, producers are exploring their incorporation into functional foods and medical supplements. This expanding application range enhances market potential, attracting speculation from major industry players who are sharp to capitalize on the growing consumer request for health-oriented items. Besides, innovations in production technology are encouraging broader utilize, thereby lifting the in general market scene.

Restraining Factor

"High Generation Controlling Costs Market Growth"

High production costs related with the complex manufacturing forms of HMOs pose a significant challenge to market growth. The intricate techniques required for union, often including specialized proteins or microbial maturation, lead to elevated costs that prevent large-scale production. As a result, the accessibility of HMOs remains limited, especially in lower-income markets. This financial boundary limits the ability of littler producers to enter the market, consolidating control among a number of major players. To overcome this restraint, ongoing research into more efficient and cost-effective production strategies is essential.

Opportunity

"Progressions Opportunity in Generation Innovations"

Later advancements in production technologies show a promising opportunity for the HMO market. Innovations in enzymatic union and fermentation forms have the potential to decrease costs significantly, making HMOs more accessible for broader applications. This technological progress not as it were empowers increased production capacity but too encourages the development of unused items catering to various consumer needs, including grown-up health supplements. As manufacturers invest in these emerging technologies, the market is likely to see a diversification of HMO applications, fostering sustained growth.

Challenge

"Administrative Challenge Obstacles"

Exploring regulatory systems presents a significant challenge for companies within the HMO market. Stricter regulations regarding food security and product labeling can obstruct the speed at which unused HMO-based items enter the market. Moreover, varying controls over different districts complicate global marketing strategies for manufacturers. Companies must allocate resources to ensure compliance with these regulations, which can redirect funds from innovation and R&D efforts. To address this challenge, partners need to lock in proactively with regulatory bodies to foster a more conducive environment for HMO item development and commercialization.

• • 

    Request a Free sampleto learn more about this report.

•  

HUMAN MILK OLIGOSACCHARIDES (HMO) REGIONAL INSIGHTS

North America

The United States Human Milk Oligosaccharides (HMO) Market, dominates, accounting for a significant share due to the tall request for infant nutrition items. Parents are increasingly looking for infant formulas enriched with HMOs, recognizing their health benefits in supporting gut health and immune work. As a result, major manufacturers are investing intensely in research and development to enhance item offerings tailored to consumer inclinations, ensuring sustained growth in this sector.

Europe

Analysts at the College of California created a groundbreaking method for producing Human Milk Oligosaccharides (HMOs) employing a novel enzymatic handle. This inventive technique significantly reduces generation costs and time whereas maintaining the basic integrity and useful benefits of HMOs. The advancement permits for large-scale synthesis, enhancing the availability of HMOs for utilize in infant equations and dietary supplements. This development not as it were addresses the high fetched barrier traditionally related with HMO production but moreover expands market openings for producers pointing to meet increasing consumer demand for health-oriented items.

Asia

They consider gives a careful analysis of the Human Drain Oligosaccharides (HMO) market, joining a comprehensive SWOT analysis that highlights qualities, weaknesses, openings, and threats inside the industry. It explores a large number of factors contributing to market growth, looking at diverse market portions and potential applications that will shape its evolution in the coming a long time. By considering both modern patterns and historical milestones, the analysis offers a well-rounded viewpoint on the market's components, pinpointing potential areas for expansion and advancement.

KEY INDUSTRY PLAYERS

"Strategic Innovation Fuels Key Industry Players in the Asia Pacific Market"

In the competitive Human Milk Oligosaccharides (HMO) Market, leading players are adopting innovative market strategies to enhance their presence. Major companies, such as Abbott and Glycom, are focusing on extensive research and development to improve production efficiencies and reduce costs. This approach not only allows them to expand their product offerings but also meets the growing consumer demand for affordable HMO-enriched infant formulas. These players are shaping vital organizations with providers and wholesalers to fortify their supply chains, guaranteeing item accessibility and situating themselves as solid sources within the commercial center. 

List of Top Human Milk Oligosaccharides (HMO) Companies

• FrieslandCampina (Netherlands)
• Glycom A/S (Denmark)
• HiSilicon Technologies (China)
• Fujifilm Diosynth Biotechnologies (U.S.)
• Inbiose (Belgium)
• Nissin Foods Holdings Co., Ltd. (Japan)
• Yinhe Biotechnology (China)

KEY INDUSTRY DEVELOPMENTS

November 2021: This inventive technique significantly reduces generation costs and time whereas maintaining the basic integrity and useful benefits of HMOs. Analysts at the College of California created a groundbreaking method for producing Human Milk Oligosaccharides (HMOs) employing a novel enzymatic handle. The advancement permits for large-scale synthesis, enhancing the availability of HMOs for utilize in infant equations and dietary supplements. This development not as it were addresses the high fetched barrier traditionally related with HMO production but moreover expands market openings for producers pointing to meet increasing consumer demand for health-oriented items.

REPORT COVERAGE

They consider gives a careful analysis of the Human Drain Oligosaccharides (HMO) market, joining a comprehensive SWOT analysis that highlights qualities, weaknesses, openings, and threats inside the industry. It explores a large number of factors contributing to market growth, looking at diverse market portions and potential applications that will shape its evolution in the coming a long time. By considering both modern patterns and historical milestones, the analysis offers a well-rounded viewpoint on the market's components, pinpointing potential areas for expansion and advancement.

The HMO market is anticipated to experience sustained growth driven by increasing consumer awareness of the wellbeing benefits related with HMOs, especially in infant nutrition and utilitarian foods. In spite of challenges such as high production costs and regulatory obstacles, the demand for items improved with HMOs continues to rise. Key industry players are focusing on technological headways and vital partnerships to upgrade their market presence and item offerings. As shopper preferences move towards health-oriented choices, the HMO showcase is well-positioned for strong development, bolstered by ongoing research and item innovation.